CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

CDK4/6 inhibitors with endocrine therapy unequivocally improve progression-free survival in HR+/HER2- advanced breast cancer.

💡 Clinical Impact

• Mechanistic: This data solidifies the role of dual pathway inhibition (estrogen receptor and cell cycle progression) in overcoming endocrine resistance, a common obstacle in advanced disease.
• Clinical/Systemic: Widespread adoption necessitates updated treatment algorithms, pharmacoeconomic evaluations, and potentially enhanced multidisciplinary team discussion for optimal patient selection and toxicity management.

📊 Evidence Breakdown Evidence Grade: 🟢 9/10 (Reconstructed Individual Patient Data Meta-Analysis of Phase III RCTs)

Analysis: This reconstructed IPD meta-analysis, drawing from pivotal Phase III RCTs, mitigates much of the heterogeneity inherent in traditional meta-analyses. The robustness of the dataset provides a clean, high-fidelity signal for efficacy.

Note: While robust, the data reflects specific trial designs and patient populations. Durability of benefit beyond reported endpoints and long-term toxicity profiles require ongoing surveillance.

🩺 Practice Recommendation [Standard of Care]: Initiate CDK4/6 inhibitors in combination with endocrine therapy for eligible patients with HR+/HER2- advanced breast cancer.

View Original Research on PubMed